Medical Condition News

RSS

Engineers discover electrical property in arteries

The heart's inner workings are mysterious, perhaps even more so with a new finding. Engineers at the University of Washington have discovered an electrical property in arteries not seen before in mammalian tissues.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

Key Surgical launches Be Healthy 2012 program

Key Surgical, a leading supplier of sterile processing and operating room supplies, is launching a year-long program to encourage its employees to adopt new, healthier lifestyles. And if the company's employees achieve a set level of healthy activities, they can earn a 1% year-end bonus - for simply getting healthier!

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

Pannexin1 protein may play an important role in mechanics of tumors

By studying tumor cell behavior in a novel "scaffold-free" 3-D system, researchers have determined that the protein Pannexin1 may play an important biomechanical role in binding tissues together, an effect that is lost in cancerous cells.

31 Jan 2012

Mayo Clinic Healthy Heart For Life! to be available online on Jan. 31

Heart disease is the nation's No. 1 killer for both men and women. But what's most astonishing is that almost 80 percent of heart disease is preventable, and even small lifestyle changes can have a big impact.

31 Jan 2012

Psychosocial interventions can reduce cancer patients' pain severity

Researchers at Moffitt Cancer Center, who teamed with colleagues at five universities around the United States, analyzed past studies of cancer-related pain reduction and found that psychosocial interventions can have a beneficial effect on cancer patients' pain severity. They also found that certain psychosocial interventions provide better pain management and are effective in reducing the degree to which pain related to cancer and its treatment interferes with patients' lives.

31 Jan 2012

MT2 gene mutations may increase risk of diabetes

Researchers in Lille and Paris demonstrated that mutations in the melatonin receptor gene (melatonin or the "hormone of darkness" induces sleep) lead to an almost sevenfold increase in the risk of developing diabetes.

31 Jan 2012

Researchers decipher genetic material of 48 pediatric glioblastomas

Glioblastomas grow extremely aggressively into healthy brain tissue and, moreover, are highly resistant to radiation therapy and chemotherapy. Therefore, they are regarded as the most malignant type of brain tumor. Currently available treatment methods are frequently not very effective against this type of cancer. Glioblastoma can affect people of all ages, but is less common in children than in adults.

31 Jan 2012

VPH's stroke center receives S. Mark Taper Foundation grant

The S. Mark Taper Foundation awarded a grant of $30,000 to Valley Presbyterian Hospital (VPH) for its Stroke Center, a state-of-the-art facility using the latest in telemedicine and diagnostic tools to ensure the best possible outcomes for its patients, Gustavo Valdespino, President and CEO of VPH, announced today.

31 Jan 2012

Alnylam receives U.S. patent allowance for LNP platform

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle (LNP) platform, including the "MC3" lipid.

30 Jan 2012

For stroke prevention, large medical centers may have the edge

Despite advances in the diagnosis and treatment of unruptured brain aneurysms, outcomes have remained stagnant over the last 10 years. This can be explained by the dramatic proliferation of minimally invasive endoscopic coiling procedures at lower-volume community hospitals, where outcomes are inferior.

30 Jan 2012

Fewer getting screened for common cancers: CDC report

According to federal health officials last Thursday, the number of Americans being screened for colon, breast and cervical cancers still fall below national targets.

30 Jan 2012

Research advances understanding of hypoxic response

A new family of proteins which regulate the human body's 'hypoxic response' to low levels of oxygen has been discovered by scientists at Barts Cancer Institute at Queen Mary, University of London and The University of Nottingham.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

FDA approves Medtronic DF4 High-Voltage Connector System for ICDs and CRT-Ds

Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and accurately treat potentially life-threatening heart rhythms.

From Medtronic 30 Jan 2012

Newly discovered molecular pathway may explain how AML develops

Researchers at UC Santa Barbara have discovered a molecular pathway that may explain how a particularly deadly form of cancer develops. The discovery may lead to new cancer therapies that reprogram cells instead of killing them. The findings are published in a recent paper in the Journal of Biological Chemistry.

30 Jan 2012

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

Applied Spectral Imaging (ASI) announced today that ASI's GenASIs Scan & Analysis, SpotScan used for the detection of chromosomal aberrations in bladder cancer has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012